Press release
Dementia Market 2032: Epidemiology Data, Pipeline Breakthroughs, Regulatory Landmarks by DelveInsight | Charsire Biotech, ProNeurogen Therapeutics, Resverlogix, Cyclerion Therapeutics, CSPC-NBP
DelveInsight's "Dementia Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Dementia, historical and forecasted epidemiology as well as the Dementia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Dementia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dementia Market Forecast [https://www.delveinsight.com/sample-request/dementia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Dementia Market Report:
*
The Dementia market size was valued approximately USD 21 million in 2021 and is anticipated to grow with a significant CAGR of 2.42% during the study period (2019-2032)
*
In 2022, the estimated total prevalence of dementia cases across the 7MM was 22,112,602, with a projected Compound Annual Growth Rate (CAGR) expected to be notably higher during the study period.
*
In 2022, there were 11,751,680 diagnosed cases of dementia identified in the 7MM, with expectations of further increases during the study period spanning from 2019 to 2032.
*
As per the Centers for Disease Control and Prevention (2022), Alzheimer's disease stands as the predominant form of dementia. Current statistics suggest approximately 5.8 million individuals in the United States are affected by Alzheimer's disease and related dementias, comprising 5.6 million individuals aged 65 and above, and roughly 200,000 individuals under 65 with early-onset Alzheimer's.
*
According to Dementia UK (2023), the estimated number of people living with dementia in the UK surpasses 900,000 individuals.
*
Key Dementia Companies: EIP Pharma Inc, Sun Pharma Advanced Research Company Limited, Pfizer, Allyx Therapeutics, BioXcel Therapeutics Inc, Prevail Therapeutics, Eli Lilly and Company, Cerevel Therapeutics, LLC, Cognition Therapeutics, Alector Inc., Athira Pharma, Otsuka Pharmaceutical Development & Commercialization, Inc., Karuna Therapeutics, CuraSen Therapeutics, Inc., Passage Bio, Inc., Suven Life Sciences Limited, Biogen, Sage Therapeutics, Transposon Therapeutics, Inc., Axsome Therapeutics, Inc., Janssen Research & Development, LLC, TrueBinding, Inc., Merck Sharp & Dohme LLC, Cassava Sciences, Inc., BioVie Inc., Vivoryon Therapeutics N.V., Alnylam Pharmaceuticals, and others
*
Key Dementia Therapies: Neflamapimod, K0706, Bosutinib, BMS-984923, BXCL501, PR006, CVL-871, CT1812, AL001, ATH-1017, AVP-786, KarXT, CST-2032, PBFT02, Masupirdine, BIIB080, SAGE-718, TPN-101, AXS-05, JNJ-63733657, Donanemab, TB006, MK-2214, Simufilam, NE3107, Aducanumab, PQ912, SAGE-718, ALN-APP, and others
*
The Dementia epidemiology based on age-specific cases analyzed that Dementia (VaD) is highly prevalent in age group of 60 years and above, while below this age group the disease appears to be rare
*
The Dementia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dementia pipeline products will significantly revolutionize the Dementia market dynamics.
Dementia Overview
An etiological category of dementia known as Dementia (VaD) is defined by significant cognitive impairment brought on by an ischemia or hemorrhagic stroke or by hypoperfusion of brain areas crucial for memory, cognition, and behavior.
Get a Free sample for the Dementia Market Report:
https://www.delveinsight.com/report-store/dementia-market [https://www.delveinsight.com/report-store/dementia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Dementia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Dementia Epidemiology Segmentation:
The Dementia market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
*
Total Prevalence of Dementia
*
Prevalent Cases of Dementia by severity
*
Gender-specific Prevalence of Dementia
*
Diagnosed Cases of Episodic and Chronic Dementia
Download the report to understand which factors are driving Dementia epidemiology trends @ Dementia Epidemiology Forecast [https://www.delveinsight.com/sample-request/dementia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Dementia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dementia market or expected to get launched during the study period. The analysis covers Dementia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Dementia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Dementia Therapies and Key Companies
*
Neflamapimod: EIP Pharma Inc
*
K0706: Sun Pharma Advanced Research Company Limited
*
Bosutinib: Pfizer
*
BMS-984923: Allyx Therapeutics
*
BXCL501: BioXcel Therapeutics Inc
*
PR006: Prevail Therapeutics/Eli Lilly and Company
*
CVL-871: Cerevel Therapeutics, LLC
*
CT1812: Cognition Therapeutics
*
AL001: Alector Inc.
*
ATH-1017: Athira Pharma
*
AVP-786: Otsuka Pharmaceutical Development & Commercialization, Inc.
*
KarXT: Karuna Therapeutics
*
CST-2032: CuraSen Therapeutics, Inc.
*
PBFT02: Passage Bio, Inc.
*
Masupirdine: Suven Life Sciences Limited
*
BIIB080: Biogen
*
SAGE-718: Sage Therapeutics
*
TPN-101: Transposon Therapeutics, Inc.
*
AXS-05: Axsome Therapeutics, Inc.
*
JNJ-63733657: Janssen Research & Development, LLC
*
Donanemab: Eli Lilly and Company
*
TB006: TrueBinding, Inc.
*
MK-2214: Merck Sharp & Dohme LLC
*
Simufilam: Cassava Sciences, Inc.
*
NE3107: BioVie Inc.
*
Aducanumab: Biogen
*
PQ912: Vivoryon Therapeutics N.V.
*
SAGE-718: Sage Therapeutics
*
ALN-APP: Alnylam Pharmaceuticals
Discover more about therapies set to grab major Dementia market share @ Dementia Treatment Market [https://www.delveinsight.com/sample-request/dementia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Dementia Market Strengths
*
The increasing prevalent population in the 7MM is likely to cause an upsurge in treatment need. Consequently, with successful launch of emerging therapies, the market will witness a boost in the upcoming year.
Dementia Market opportunities
*
Medications with better safety and effectiveness, which provide optimum care are the current unmet need of the VaD disease market.
Scope of the Dementia Market Report
*
Study Period: 2019-2032
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Dementia Companies: EIP Pharma Inc, Sun Pharma Advanced Research Company Limited, Pfizer, Allyx Therapeutics, BioXcel Therapeutics Inc, Prevail Therapeutics, Eli Lilly and Company, Cerevel Therapeutics, LLC, Cognition Therapeutics, Alector Inc., Athira Pharma, Otsuka Pharmaceutical Development & Commercialization, Inc., Karuna Therapeutics, CuraSen Therapeutics, Inc., Passage Bio, Inc., Suven Life Sciences Limited, Biogen, Sage Therapeutics, Transposon Therapeutics, Inc., Axsome Therapeutics, Inc., Janssen Research & Development, LLC, TrueBinding, Inc., Merck Sharp & Dohme LLC, Cassava Sciences, Inc., BioVie Inc., Vivoryon Therapeutics N.V., Alnylam Pharmaceuticals, and others
*
Key Dementia Therapies: Neflamapimod, K0706, Bosutinib, BMS-984923, BXCL501, PR006, CVL-871, CT1812, AL001, ATH-1017, AVP-786, KarXT, CST-2032, PBFT02, Masupirdine, BIIB080, SAGE-718, TPN-101, AXS-05, JNJ-63733657, Donanemab, TB006, MK-2214, Simufilam, NE3107, Aducanumab, PQ912, SAGE-718, ALN-APP, and others
*
Dementia Therapeutic Assessment: Dementia current marketed and Dementia emerging therapies
*
Dementia Market Dynamics: Dementia market drivers and Dementia market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Dementia Unmet Needs, KOL's views, Analyst's views, Dementia Market Access and Reimbursement
To know more about Dementia companies working in the treatment market, visit @ Dementia Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/dementia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Dementia Market Report Introduction
2. Executive Summary for Dementia
3. SWOT analysis of Dementia
4. Dementia Patient Share (%) Overview at a Glance
5. Dementia Market Overview at a Glance
6. Dementia Disease Background and Overview
7. Dementia Epidemiology and Patient Population
8. Country-Specific Patient Population of Dementia
9. Dementia Current Treatment and Medical Practices
10. Dementia Unmet Needs
11. Dementia Emerging Therapies
12. Dementia Market Outlook
13. Country-Wise Dementia Market Analysis (2019-2032)
14. Dementia Market Access and Reimbursement of Therapies
15. Dementia Market Drivers
16. Dementia Market Barriers
17. Dementia Appendix
18. Dementia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dementia-market-2032-epidemiology-data-pipeline-breakthroughs-regulatory-landmarks-by-delveinsight-charsire-biotech-proneurogen-therapeutics-resverlogix-cyclerion-therapeutics-cspcnbp]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dementia Market 2032: Epidemiology Data, Pipeline Breakthroughs, Regulatory Landmarks by DelveInsight | Charsire Biotech, ProNeurogen Therapeutics, Resverlogix, Cyclerion Therapeutics, CSPC-NBP here
News-ID: 3492797 • Views: …
More Releases from ABNewswire
Chazin & Company Announces Three Grants to Arizona Nonprofits as Part of its Ina …
Mission driven financial solutions experts shows solidarity with Arizona community organizations.
Chazin & Company [https://www.chazinandcompany.com/], a leading provider of outsourced accounting and finance services for nonprofit organizations nationwide, today announced it has awarded three $5,000 unrestricted grants to Arizona nonprofits as part of its first-ever Roadshow event.
The May 20 Chazin Roadshow in Arizona is the first event in a series that Chazin & Company plans to hold around the country. Organizers…
YADAH Leads the Vegan Beauty Revolution with High-Quality, Eco-Friendly Products
Image: https://www.abnewswire.com/uploads/a226cf602a97874c8bfe654d3527841e.png
28th May, 2024 - Amidst the growing popularity of vegan cosmetics in the beauty market, YADAH (YADAH, CEO Kang Eun-mi) is at the forefront of the vegan beauty trend by developing products with high-quality ingredients that are not harmful to the skin.
Since its establishment in 2011, YADAH has consistently avoided the use of animal-derived or tested ingredients, harmful substances, even before "vegan beauty" became a trend. The company has…
Global Aircraft Electric Motors Market Set to Reach New Heights by 2027
The Global Aircraft Electric Motors Market Size is projected to grow from USD 8.2 billion in 2022 to USD 12.9 billion by 2027, at a CAGR of 9.4% from 2022 to 2027.
The global Aircraft Electric Motors [https://www.marketsandmarkets.com/Market-Reports/aircraft-electric-motors-market-3248447.html] Market is poised for significant growth, driven by advancements in electric propulsion technology and increasing demand for more efficient and environmentally friendly aircraft. According to a comprehensive report by MarketsandMarkets, titled "The Global…
Water-soluble Fertilizers Market Size, Industry Overview, Trends, Opportunities, …
Water-soluble Fertilizers Market by Type (Nitrogenous, Phosphatic, Potassic, and Micronutrients), Mode of Application (Foliar and Fertigation), Form (Dry and Liquid), Crop Type and Region - Global Forecast to 2028
The [https://www.prnewswire.com/news-releases/water-soluble-fertilizers-market-worth-23-9-billion-by-2028-exclusive-report-by-marketsandmarkets-301809507.html] is projected to reach $25.1 billion by 2028 from $18.3 billion in 2023, growing at a CAGR of 6.5% from 2023 to 2028. The water-soluble fertilizer industry has experienced a shift in demand due to changing consumer preferences and an…
More Releases for Dementia
Dementia Care APP Market Is Booming Worldwide 2021-2027 | Dementia Digital Diary …
Global Dementia Care APP market 2020-2026 in-depth study accumulated to supply latest insights concerning acute options. The report contains different predictions associated with Dementia Care APP market size, revenue, production, CAGR, consumption, profit margin, price, and different substantial factors. Whereas accentuation the key driving and Dementia Care APP restraining forces for this market, the report offers trends and developments. It additionally examines the role of the leading…
Dementia screening and prevention – hope or hype?
It is estimated that about 50% of dementia patients do not receive a formal diagnosis. And when the diagnosis is made, it often happens at a time when the disease is well advanced and brain damages are irreversible.
A major reason for this is that systematic dementia screening and prevention programmes are not yet ready for implementation as large-scale public health interventions. A key reason for this is the desire…
Dementia Treatment
Dementia Drugs and Treatment Market describes its growth, size, share, Forecast and trends to 2025
The global Dementia Drugs and Treatment market is valued at 13900 million US$ in 2018 is expected to reach 26500 million US$ by the end of 2025, growing at a CAGR of 8.4% during 2019-2025.
This report focuses on Dementia Drugs volume and value at global level, regional level and company level. From a global perspective, this…
New App detects dementia risks early
• The App is certified as a Medical Device.
• Early stages are reliably detected, before the brain damage becomes irreversible.
• Sensitivity above 96%, significantly higher than with the established tests (e.g., MMSE 71%).
• Now available for free during pre-launch.
Dementia is a rapidly increasing social problem of a rapidly aging society. Because until today there is no effective therapy for advanced stages of dementia.
Therefore, effective screening tests are needed to detect early stages…
2nd International Conference on Dementia and Dementia Care
Breakthrough in Dementia Research and Care
Event Name: 2nd International Conference on Dementia and Dementia Care (Dementia 2019)
Theme: Breakthrough in Dementia Research and Care
Aim and Scope: Dementia is an umbrella term used to describe a set of symptoms that occur when the brain is affected by disease. There’s currently no cure and no treatment that slows or stops its progression, but there are things you can do to help reduce the…
11th International Conference on Vascular Dementia
Can We Cure Dementia, Vascular Dementia and Alzheimer's disease?
It’s our pleasure to invite all the participants from all over the world to attend the 11th International Conference on Vascular Dementia which is held during February 15-16, 2019 Amsterdam| Netherlands.
Vascular Dementia conference will assemble illustrious speakers, Researchers, Nobel laureates, Neurologists, and Neuroscience researchers from both academic and health care professionals will join this event to discuss their views and research. The…
